NIKLAS RYE JØRGENSEN, JULY 2014 - Rigshospitalet · Niklas Rye Jørgensen • 61670065• [email protected] Page 7 1. Jørgensen NR, Syberg S, Ellegaard M. P2X receptor roles in

CV

NIKLAS RYE JØRGENSEN, JULY 2014

Niklas Rye Jørgensen • 61670065• [email protected] Page 2

INDEX

1. PERSONAL INFORMATION 3

2. PROFESSIONAL QUALIFICATIONS 3

2.1 Educational record 3

2.2 Special courses 3

2.3 Appointments (full time) 4

2.4 Appointments (part time, consultancy etc.) 5

3. SCIENTIFIC QUALIFICATIONS 5

3.1 Academic degrees 5

3.2 Publications 5

3.3 Membership of scientific societies 7

4. MANAGEMENT AND ADMINISTRATIVE FUNCTION 8

4.1 Education and courses 8

4.2 Managerial and administrative experience 8

4.3 Chairmanship 8

4.4 Membership of professional committees and councils 9

4.5 Other honorary offices 9

5. EDUCATION OF POSTGRADUATE STUDENTS AND THE LIKE 9

5.1 Supervision of postgraduate students and PhD students 9

5.2 Supervision of pregraduate students 10

5.3 Contribution to postgraduate courses 11

5.4 Pregraduate teaching 14

6. EVALUATION 14

6.1 Membership of scientific editorial board 14

6.2 Reviewing of articles 14

6.3 Membership of evaluation committees for academic personnel 14

6.4 Membership of evaluation committees for academic dissertations 14

6.5 Membership of research councils 15

7. RESEARCH COMMUNICATION 15

7.1 Invited lectures at conferences and meetings 15

7.2 Chairman at international scientific conferences 17

7.3 Other scientific papers and posters 17

7.4 Publications and presentations in popular scientific connection 23

8. RESEARCH FUNDING 24

8.1 Funding awards held during the last five years 24

8.2 Participation in international research programmes 24

8.3 Existing commercial collaborations 24

9. RESEARCH COLLABORATIONS 25


1. PERSONAL INFORMATION

Name: Niklas Rye Jørgensen

Age: Born 1967

Address: Axel Heides Gade 2, 6. lejl. 4

2300 København S

Phone: 35 34 00 20 (home)

61 67 00 65 (mobile)

Email: [email protected]

2. PROFESSIONAL QUALIFICATIONS

2.1 EDUCATIONAL RECORD

Student (Math-Biology) Niels Steensen’s Highschool June 1985 Medical Doctor University of Copenhagen June 1992 PhD (Medicine) University of Copenhagen March 2000 Doctor of Medical Science University of Copenhagen October 2005 Specialist Clinical Biochemistry Danish Health Agency March 2009

2.2 SPECIAL COURSES

MANAGEMENT

1. Ledelse , adm. og samarbejde (LAS II) Comwell, Roskilde 20.-22. Oct., 3. Nov. 2008 2. Ledelse, adm. og samarbejde (LAS III) Glostrup Park Hotel 27.-30. January 2009 3. Ledertalentudviklingsforløb Region Hovedstaden June 2011 4. OLAU Grundmodul Hindsgavl Castle 20.-24. September 2010 5. Læge og Leder – Ledelse af Fagprofessionelle Hindsgavl Castle 26. March -13. June 2012

6. Ledelse af Forskning (Research Management) Region Hovedstaden Fall/winter 2014/2015

CLINICAL BIOCHEMISTRY

1. Endocrinology Domus Medica 25.-26. October 2004 2. Reproductive system Roskilde Hospital 22.-23. August 2005 3. Cardiovascular diseases Rigshospitalet 21.-23. November 4. Metabolism Odense University Hospital 10.-12. October 2006 5. Thrombosis and Haemostasis Esbjerg Hospital 8.-10. October 2007 6. Haematology Hvidovre Hospital 21.-23. November 2007

7. Pharmacology and toxicology Vejlefjord 4.-6. November 2008

PHD COURSES


1. Cellular immunology University of Copenhagen 16.-22. November 1995 2. Optical microscopy (34 lessons) Washington University Spring 1996 3. Light microscopy and imaging University of Copenhagen 18.-22. August 1997 4. Reference Manager for Windows Danish National Library 3. October 1997 5. Basic statistics for medical researchers University of Copenhagen January-April 1998 6. Immunochemical methods University of Copenhagen 15.-22. January 1999 7. In vitro gene expression University of Copenhagen 1.-5. February 1999

EU FUNDING RELATED

1. Vejen til en god ansøgning til EU FP7 Eurocenter 19. februar 2007 2. Budgetter og regnskaber i FP7 Eurocenter 21. April 2009 3. Styr dit FP7 projekt sikkert I havn Eurocenter 4. November 2009 4. Snyd ikke dig selv i et FP-7 projekt Eurocenter 5. November 2009

OTHER

1. Courses in sports medicine Danish Soc. for Sports Med. 1992-1993 2. Acupuncture basic course Danish Soc. for Acupuncture 21.-22. January 1994 3. Practical use of acupuncture Sheffield, UK February 1994 4. Acupuncture course V.A. Danish Soc. for Acupuncture 30. April-3. May 1998 5. Polymerase Chain Reaction (PCR) Hvidovre Hospital 15.-16. June 2000 6. Patent Conditions (24 lessons) Danish Research Agency 20.-22. November 2000 7. Genetic therapy University of Copenhagen 14.-16. May 2001 8. Laboratory animal science (30 lessons) University of Copenhagen January 2002 9. Bone histomorphometry (ECTS course) Aarhus University 28.-30. October 2002 10. SPSS Basic Uni-C 11.-12. December 2002 11. SPSS Regression analysis Uni-C 24.-25. February 2003 12. SPSS Regression analysis Uni-C 13.-14. May 2009 13. Bone histomorphometry Vienna, Austria 23. May 2009 14. Media Training Course Dethlefsen Communication 30. April 2013

CONFERENCES

Annual participation in scientific conferences within the relevant fields including American Society for Bone and Mineral Research (ASBMR), European Calcified Tissue Society (ECTS), Purines, Clinical Biochemistry, Cell Biology etc.

2.3 APPOINTMENTS (FULL TIME)

1. Medicine (7 months) Resident Dept. of Int. Medicine, Fakse Hospital 010892-280293 2. Surgery (6 months) Resident Dept. of Surgery, Fakse Hospital 010393-310893 3. General medicine (6 months) Resident General Practice, Stokkemarke 010993-290294 4. Medicine/endocrinology (12 months) Fellow Dept. of Endocrinology, Hvidovre Hospital 010394-280295 5. Research (57 months) Research fellow, Osteoporosis Res. Center, Copenhagen Mun. Hosp. 010395-301199

6. Research (6 months) Visit. res. fellow Washington University in St. Louis, MO, USA 010196-300696 7. Research (39 months)


Post doc/group leader Osteoporosis Research Clinic, Hvidovre Hospital 011299-280203 8. Clinical Biochemistry (54 months) Fellow (spec.training) Dept. of Clinical Biochemistry, Hvidovre Hospital 010303-310807 9. Clinical Biochemistry (18 months) Fellow (spec. training) Dept. of Clinical Biochemistry, Roskilde Hospital 010907-280209 10. Research (3 months) Consultant Res. Center for Ageing and Osteop., Glostrup Hosp. 010309-310509 11. Clinical Biochemistry (31 months) Consultant Dept. of Clinical Biochemistry, Glostrup Hospital 010609-311211 12. Clinical Biochemistry (31 months per 31. August 2014) Head of Division Division of Clinical Biochemistry, Dept. of Diagnostics, Glostrup Hospital 010112-cont.

2.4 APPOINTMENTS (PART TIME, CONSULTANCY ETC.)

TEACHING

1. Teacher Niels Steensen’s Highscool /Schools in Ishøj 010885-300688 2. Associate professor Institute of Public Health, University of Copenhagen 010200-310103 3. Lecturer (clin. bioch.) Hvidovre Hospital/University of Copenhagen 010303-310807 4. Associate professor Roskilde University 010208-280209 5. Tutor for MDs Div of Clinical Biochemistry, Glostrup Hospital 2011-cont. 6. Assoc. research prof. University of Copenhagen 010813-cont.

RESEARCH RELATED

1. Medical consultant Zealand Pharma A/S (development of gap junction 2000-2004 modifiers as anti-osteoporotic drugs) 2. Lab director Res. Center for Ageing and Osteop, Glostrup Hosp. 010907-cont. 3. Clinical Assessor Danish Medicines Agency, Div. of Clin. Trials 011201-cont. (Evaluation of clinical trial applications and safety)

3. SCIENTIFIC QUALIFICATIONS

3.1 ACADEMIC DEGREES Medical Doctor University of Copenhagen June 1992 PhD (medicine) University of Copenhagen March 2000 Doctor of Medical Science University of Copenhagen October 2005

3.2 PUBLICATIONS

PEER-REVIEWED PUBLICATIONS Total number of peer-reviewed publications (per August 1st 2014): 83

Number of these within the past five years (2009-2014): 49

SELECTED PUBLICATIONS The publications enclosed with the application have been selected as they are relevant to the research areas in the professorate. Publication # 1-5 relates to “cellular and physiological mechanisms for the effects of mechanical loading and unloading”, # 6-10 relates to “purinergic signaling in health and disease” and finally #11-12 relates to “clinical use of biomarkers of bone


turnover”. As the implementation of bone turnover markers is relatively new in our department, we have only started to publish on this recently. and the number of publications in this field is still limited. Please find justification for including the individual publications in brackets adjacent to the publication. 1. Jørgensen NR, Syberg S, Ellegaard M. P2X receptor roles in bone biology. Current Medicinal

Chemistry 2014; in press. (Invited review – gives the latest overview of the role of P2X receptors

in bone biology, health and disease) 2. Kringelbach TM, Aslan D, Novak I, Schwarz P, Jørgensen NR. UTP-induced ATP-release is a fine-

tuned signalling pathway in osteocytes. Purinergic Signalling 2014; XX:xxx-xxx. (Key publication

demonstrating the role of purinergic signaling in osteocyte biology) 3. Jørgensen NR, Henriksen Z, Sørensen OH, Eriksen EF, Civitelli R, Steinberg TH. Intercellular

calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem 2002; 277: 7574-7580. (Provides evidence that purinergic

signaling is responsible for mechanically induced signaling between osteoblasts and osteoclast). 4. Jørgensen NR, Henriksen Z, Brot C, Sørensen OH, Eriksen EF, Civitelli R and Steinberg TH.

Intercellular calcium waves in human osteoblasts occur by two different mechanisms. J Bone Min Res 2000;15:1024-1032. (Demonstrated the presence of two mechanisms for mechanically

induced signaling among osteoblasts) 5. Jørgensen NR, Geist ST, Civitelli R and Steinberg TH. ATP- and gap junction-dependent

intercellular calcium signaling in osteoblastic cells. J Cell Biol 1997; 139: 497-506. (One of the first

publications to demonstrate purinergic signaling among osteoblastic cells) 6. Vangsted A, Klausen T, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmström M,

Gregersen H, Vogel U, Schwarz P, Jørgensen NR. Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. Eur J Haematol 2014; 93:172-174. (This publication

shows that genetic alterations in the P2X7 receptor gene has profound consequences for

development of myeloma bone disease) 7. Jørgensen NR, Skarratt KK, Husted LB, Tofteng CL, Stokes L, Jensen JEB, Eiken P, Brixen K, Fuller

S, Clifton-Bligh R, Gartland A, Langdahl BL, Schwarz P, Wiley JS. Single nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Human Genetics 2012;20;675-681. (Demonstrating the role of P2X7 receptor

polymorphisms in bone health and disease in the Danish Osteoporosis Prevention Study) 8. Jørgensen NR, Grove EL, Schwarz P, Vestergaard P. Clopidogrel and risk of osteoporotic factors –

a nationwide cohort study. J Int Med 2012;272:385-392. (Showing the bone –related side effects

of clopidogrel, which was the first drug targeting purinergic receptors) 9. Vestergaard P, Schwarz P, Steinberg TH, Jørgensen NR. Use of the oral platelet inhibitors

dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 2011;160:36-40. (Our first publication to address the bpne effects of clopidogrel)

10. Ohlendorff SD, Tofteng CL, Jensen JEB, Petersen S, Civitelli R, Fenger M, Abrahamsen B Hermann P, Eiken P, Jørgensen NR. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenetics Genomics 2007; 17,555-567. (The first publication to ever investigate the association between P2 receptor polymorphisms and

bone health and disease) 11. Shanbhogue VS, Hansen S, Jørgensen NR, Brixen K, Gravholt CH. Bone geometry, volumetric

density, microarchitecture and estimated bone strength assessed by HR-pQCT in Klinefelter syndrome. J Bone Min Res 2014; in press. (Our first collaborative publication on bone turnover

markers, made in collaboration with SDU/OUH) 12. Helge EW, Andersen TR, Schmidt JF, Jørgensen NR, Hornstrup T, Krustrup P, Bangsbo J.

Recreational football improves bone mineral density and bone turnover marker profile in elderly men. Scand J Med Sci Sports 2014; Suppl.1:98-104. (The first publication from a line of

collaborative projects on the effects of physical activity on bone mass as measured by bone

turnover markers)

MOST IMPORTANT REVIEW ARTICLES


1. Jørgensen NR, Syberg S, Ellegaard M. P2X receptor roles in bone biology. Current Medicinal Chemistry 2014; in press.

2. Jørgensen NR, Schwarz P. Effects of anti-osteoporosis medications on fracture healing. Curr Reports Osteoporosis 2011; 9,149-155.

3. Jørgensen NR, Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients. Current Opinion Pulmonary Medicine 2008; 14:122-127.

4. Jørgensen NR. Short-range intercellular calcium signalling in bone. APMIS 2005; 113 (suppl.118):1-37.

5. Jørgensen NR, Steinberg TH, Civitelli R. Osteoblast-Osteoclast Communication. Current Opinion in Orthopedics 1999; 10:367-73.

OTHER SCIENTIFIC PUBLICATIONS

Original articles: 53 Editorials: 1 Proceedings: 2 Reviews: 22 Book chapters: 3 Patent applications: 2 Other publications: 5 Publications submitted or close to submission: 12

TEXT BOOKS AND CONTRIBUTIONS TO TEXT BOOKS

1. Civitelli R, Stains JP, Shin CS, Jørgensen NR. Intercellular junctions and cell-cell communication in the skeletal system. p. 423-444. In: Principles of Bone Biology, eds: Bilezikian JP, Raisz LG. 2008. Academic Press, San Diego, CA.

2. Jørgensen NR, Steinberg TH. Purinergic signaling in osteoblasts. p. 1-24. In: Nucleotides and regulation of bone cell function. Eds: Burnstock G, Arnett T. 2006. CRC Press, Boca Raton, FL.

3. Civitelli R, Lecanda F, Jørgensen NR, Steinberg TH. Intercellular junctions and cell-cell communication in bone. p. 287-302. In: Principles of Bone Biology, eds: Bilezikian JP, Raisz LG, Rodan GA. 2002. Academic Press, San Diego, CA.

3.3 MEMBERSHIP OF SCIENTIFIC SOCIETIES

1. The New York Academy of Sciences

2. European Calcified Tissue Society

3. American Society for Bone and Mineral Research

4. American Society for Cell Biology

5. The Society for Theoretical and Applied Therapy (Jakobinerklubben) 6. The Danish Endocrine Society

7. The Danish Bone Society

8. The Danish Society for Clinical Biochemistry

4. MANAGEMENT AND ADMINISTRATIVE FUNCTION


4.1 EDUCATION AND COURSES

1. Ledelse , adm. og samarbejde (LAS II) Comwell, Roskilde 20.-22. Oct. and 3. Nov. 2008 2. Ledelse, adm. og samarbejde (LAS III) Glostrup Park Hotel 27.-30. January 2009 3. Ledertalentudviklingsforløb Region Hovedstaden June 2011 4. OLAU Grundmodul DADL (Hindsgavl) 20.-24. September 2010 5. Læge og Leder – Ledelse af Fagprof. DADL (Hindsgavl) 26. March -13. June 2012

(included exam, 3 ECTS points)

6. Ledelse af Forskning ) Region Hovedstaden Fall/winter 2014/2015 (accepted for participation)

4.2 MANAGERIAL AND ADMINISTRATIVE EXPERIENCE

CONTINUOUS MANAGERIAL AND ADMINISTRATIVE FUNCTIONS 1. Head of Division of Clinical Biochemistry (specialeansvarlig overlæge) 010112-cont. Glostrup Hospital 2. Lab Director, Research Center for Ageing and Osteoporosis 010309-cont. Glostrup Hospital 3. Group leader for own research group (P2 Bone lab) 2002-cont. Osteoporosis Research Clinic, Hvidovre Hospital and Research Center for Ageing and Osteoporosis EXPERIENCE WITH STAFF AND FINANCIAL ADMINISTRATION

1. As group leader of my own research group over the years

I have the responsibility for administration of staff and financial issues 2002-cont. 2. Several grants obtained, in which I had the responsibility for

administration of finances and for reporting to the funding agencies 2000-cont. 3. Member of the evaluation committee for employment of the head

of Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. 2004 4. Chairman of the evaluation committee for senior consultant for

Division of Clinical Biochemistry, Glostrup Hospital, Denmark. 2011 5. Chairman of the evaluation committee for chemist at the

Division of Clinical Biochemistry, Glostrup Hospital, Denmark. 2013 6. Member of evaluation committees for employing technicians 2012-cont.

at the Division of Clinical Biochemistry (several) 7. As coordinator and chairman of the board of the ATPBone consortium

funded by the EU’s 7th Framework Programme, I had the administrative and financial responsibility for the grant

4.3 CHAIRMANSHIP Chairman of the Board and Scientific Coordinator for the ATPBone 2008-2010 Consortium, which was funded by the EU’s 7th Framework Programme

4.4 MEMBERSHIP OF PROFESSIONAL COMMITTEES AND COUNCILS


1. Board member of Gruppen af Unge Forskere i H:S (GUF) 1995-1999 2. Member of Steering Committee for development of a joint intranet 2000-2002 in Copenhagen Hospital Corporation (H:S) 3. Member of Scientific Advisory Board, Zealand Pharma A/S 2003-2004 4. Member of the Research Council of The Copenhagen 2004-2006 Hospital Corporation (H:S) 5. Board member of the Danish Bone Society 2006-2010 6. Member of the Danish Council for Education in Clinical Biochemistry 2006-cont. (Videreuddannelsesrådet, Region Øst) 7. Member of the Committee for Harmonization in Clinical Biochemistry 2010-2012 In Region Hovedstaden (Harmoniseringsgruppen) 8. Treasurer of and Danish representative in the Board of the Nordic 2009-2010 Society for Clinical Chemistry 9. Member of the Council for Clinical Biochemistry (Sundhedsfagligt Råd) 2012-cont. in Region Hovedstaden 10. Member of the Committee for establishment of the Danish Rheuma 2013-cont. Biobank 11. Co-founder of and member of steering committee for establishment 2013-cont. of a consortium for an inter-European project on diabetic complications and purinergic receptor signaling as drug targets 12. Board member of the Danish Bone Society 2013-cont. 13. Co-opted member of the Committee of Scientific Advisors for the 2013-cont. International Osteoporosis Foundation (IOF) 14. Member of IOF Working Group on “Bone Turnover Markers” and 2014-cont. “Diabetes and Osteoporosis” 15. Member of Project Management Team, CoNeXT project, funded by 2013-cont. University of Copenhagen (Puljen for interdiscipl. forskning).

4.5 OTHER HONORARY OFFICES Danish contact for Washington University International Alumni and 2000-2007 Development Programs

5. EDUCATION OF POSTGRADUATE STUDENTS AND THE LIKE

5.1 SUPERVISION OF POSTGRADUATE STUDENTS AND PHD STUDENTS SUPERVISION OF PHD STUDENTS 1. Stine Ohlendorff (MSc) on her project: “Single nucleotide polymorphisms in the P2X7

receptor: association with bone mass and fracture risk”. Roskilde University 2000-2004. PhD awarded March 2006. Was the main supervisor, but not the university supervisor.

2. Susanne Syberg Hansen (MSc) on her project: “Characterization of a novel P2X7 knockout model, implicates a role for P2X7 in bone metabolism”. Roskilde University 2004-2009 (she had maternity leave x 2). PhD awarded February 2011. Served as main supervisor, but not the university supervisor.

3. Tina Marie Kringelbach (MSc) on her project: “P2 purinergic receptors in osteocyte signalling”. University of Copenhagen 2008-2013 (she had maternity leave x 2). PhD awarded June 2014. Served as main supervisor, but not the university supervisor.


4. Katarzyna Gurzawska (cand. odont.) on her project: “Nanocoating of implant surfaces with pectin rhamnogalacturonan-Is”. University of Copenhagen 2008-2012. PhD awarded March 2013. Co-supervisor.

5. Maria Ellegaard Larsen (MSc) on her project: “Parathyroid hormone and bone healing”. University of Copenhagen 2008-2012. PhD awarded May 2013. Co-supervisor.

6. Torben Madsen Kvist (MD) on his project: “The role of P2X7 receptors in immune-mediated bone loss. University of Copenhagen 2010-2013. Thesis awaiting submission. Co-supervisor.

7. Camilla Albeck Neldam (cand. odont.) on her project: “3D microarchitecture – rods, plates and µ-gap – of peri-implant hard tissues – evaluated by synchrotron µCT radiation and histomorphometry”. University of Copenhagen 2014-cont. Principal supervisor.

8. Morten Dahl (cand. odont.) on his project: “Mesenchymal stem cell osteoblast mineralization”. University of Copenhagen 2013-cont. Principal supervisor.

SUPERVISION OF POST DOCS 1. Susanne Syberg Nielsen on several projects:

a. P2X7 antagonists in the treatment of osteoporosis b. The negative effects on bone of platelet inhibitors targeting the P2Y12 receptor c. Bone turnover marker measurements – stability, validity and reference ranges d. P2X7 receptor polymorphisms and their effects on bone cell function

2. Maria Ellegaard Larsen on several projects a. Mechanisms for loading and unloading effects on bone with special focus on

purinergic signalling b. Role of P2 receptor polymorphisms in osteoporosis in men c. 3D methods to enhance osteocyte culturing and phenotype in vitro

SUPERVISION OF MEDICAL DOCTORS 1. Anne Louise Knudsen, MD during her specialist training at Division of Clinical Biochemistry,

Glostrup Hospital. 2012-2014. 2. Young Bae Villy Lee Hansen, MD during his specialist training at Division of Clinical

Biochemistry, Glostrup Hospital. 2013-2015.

5.2 SUPERVISION OF PREGRADUATE STUDENTS

SUPERVISION OF PREGRADUATE MASTER PROJECTS 1. Stefan Cuoni Teilmann BSc master project: “Gap junction openers: Effects on intercellular

communication in bone cells”. Roskilde University 2000-2001. Main supervisor. 2. Susanne Syberg Hansen BSc master project: “The synthetic peptide ZP123 increases gap

junctional intercellular communication in human osteoblasts”. Roskilde University 2002-2003. Main supervisor.

3. Rikke Rye Aarup (BSc) master project: ”Single nucleotide polymorphisms in the purinergic P2Y2 receptor and association to bone status”. Roskilde University 2006-2007. Main supervisor.

4. Maria Ellegaard Larsen (BSc) master project: “The effect of amylin(1-8) on bone in ovariectomized rats”. University of Copenhagen 2006-2007. Co-supervisor.

5. Tina Marie Kringelbach (BSc) master project: “The expression, functions and regulation of P2 purinergic receptors in osteocytes”. Roskilde University 2007-2008. Main supervisor.

SUPERVISION OF OTHER PREGRADUATE PROJECTS 1. Stefan Cuoni Teilmann (BSc) project: “Intercellular calcium signaling in osteoblast-like cells:

An investigation of gap junction mediated calcium wave propagation”. Roskilde University 1998-1999. Main supervisor.


2. Barbara Rubek Nielsen (stud.med.) OSVAL II project: “Management of risk of glucocorticoid induced osteoporosis due to systemic administration in general practice in Denmark”. University of Copenhagen 2004-2005. Co-supervisor.

3. Marie Solgaard (stud.med.) OSVAL II project: “P2 purinergic receptors in human osteoblasts”. University of Copenhagen 2004-2005. Main supervisor.

4. Maria Ellegaard Larsen (BSc) project: “The OPG/RANKL system and the role in regulation of bone remodeling”. University of Copenhagen 2005. Co-supervisor.

5. Zanne Henriksen (BSc) project: “Calcium signaling during osteoblasts differentiation”. Roskilde University 2005. Main supervisor.

6. Anne Qvist Rasmussen (BSc) project: “Mutations in the calcium sensing receptor”. Roskilde University 2005. Main supervisor.

7. Nina Geiker and Rikke Larsen (BSc) project: “Vitamin D status in elite athletes”. University of Copenhagen 2007. Co-supervisor.

8. Lasse Maretty Sørensen (stud.med.) OSVAL I project: ”Adipocyte-osteoblast transdifferentiating potential”. University of Copenhagen 2007. Main supervisor.

9. Tore Lefolii (stud.odont.) project: ”Tooth implants in osteoporotic rabbits”. University of Copenhagen 2007-2008. Co-supervisor.

10. Derya Aslan, Mille Dahl Andersen, Lene Bjerring Gede, Sara Rubek Jørgensen and Tine Kellemann Hansen (BSc) project: ”Osteoporosis and parathyroid hormone”. Roskilde University 2008. Main supervisor.

11. Morten Dahl (stud. odont.) scholarship project: “Titanium granules and the effect on differentiation of adipocyte progenitors into osteoblasts”. University of Copenhagen 2010. Co-supervisor.

12. Jan Larsen, Barakat Ali and Thomas Jensen (Bsc) project: “Mechanotransduction in osteocytes”. Roskilde University 2011. Main supervisor.

5.3 CONTRIBUTION TO POSTGRADUATE COURSES

ORGANIZER OF POSTGRADUATE COURSES 1. Member of the board/steering group for the PhD school “Skeletal Sciences”, University of

Copenhagen, 2011-2014. 2. Member of the board for the PhD school “Basic and Clinical Research in Musculoskeletal and

Oral Sciences”. From 2014-cont. 3. Co-organizer of A-course in clinical biochemistry: “Haematology”, Hvidovre Hospital 21.-23.

November 2007 4. Co-organizer of and course facilitator of compulsory course in research methods (Statistics)

for physicians in specialist training (Obligatorisk Forskningstræningskursus for læger I hoveduddannelsesforløb). Three-day course. Has done this app. 25 times since 2007.

5. Co-organizer of PhD course: “Basic Bone Biology”. PhD school “Skeletal sciences”, University of Copenhagen 3.-7. October 2011.

6. Co-organizer of PhD course: “Physical activity: Bone and muscle in the old and oldest old”. PhD school “Skeletal sciences”, University of Copenhagen 23.-27. April 2012.

7. Co-organizer of A-course in clinical biochemistry: “Endocrinology”. Responsible for planning the session on bone metabolism and vitamin D. Vejle 7.-9. October 2014.

8. Member of working group planning and evaluating the compulsory research training courses (obligatorisk forskningstræningskurser) Modul II. From 2009-cont.

ORGANIZER OF SCIENTIFIC MEETINGS AND CONFERENCES 1. Organizer of symposium on bone in tribute to Dr. Ole Helmer Sørensen. Hvidovre Hospital,

August 2002 2. Organizer of meeting on “Intercellular communication in bone” in the Danish Bone Society.

Hvidovre Hospital, November 2003.


3. Organizer of meeting on “In vitro and in vivo models in osteoporosis and bone research” in the Danish Bone Society. Hvidovre Hospital, April 2007.

4. Organizer of ATPBone minisymposium at Purines 2008. Copenhagen, June 2008. 5. Organizer of meeting on “Physical activity and osteoporosis” in the Danish Bone Society.

Glostrup Hospital, November 2008. 6. Co-organizer of meeting on “The calcium-sensing receptor” in the Danish Bone Society.

Glostrup Hospital, May 2009. TEACHING IN POSTGRADUATE COURSES (PHD)

1. “Calcium in the cross-talk between bone cells”. PhD course at DIBIT Research Institute, San Raffaele Hospital, Milan, Italy. April 2006.

2. “Intercellular calcium signaling in bone”. PhD course on “Bone biology” at Aarhus University, Denmark. October 2007.

3. “Intercellular calcium signaling in bone or how exercise builds strong bones”. PhD course in “Bone biology” at Aarhus University, Denmark. October 2010.

4. “Intercellular signaling in bone”. PhD course on “Bone Biology”, PhD school of “Skeletal Science” at University of Copenhagen, Denmark. October 2011.

5. “Regulation of synthesis and degradation of bone matrix”. PhD course on “Matrix biology” at Faculty of Health Sciences, University of Copenhagen, Denmark. October 2013.

6. “Regulation of synthesis and degradation of bone matrix”. PhD course on “Matrix biology” at Faculty of Health Sciences, University of Copenhagen, Denmark. November 2014.

TEACHING IN POSTGRADUATE COURSES (COURSES FOR PHYSICIANS IN SPECIALTY TRAINING)

1. “The calcium homeostasis”. A-course on “Endocrinology” for physicians in training in Clinical Biochemistry, Vejle, Denmark. November 2005.

2. “Calcium signaling in bone cells-presentation of a research project”. A-course on “Endocrinology” for physicians in training in Clinical Biochemistry, Vejle, Denmark. November 2005.

3. “Basic principles of laboratory research”. Compulsory research course for physicians in specialty training (Obligatorisk Forskningstræningskursus Modul 1), University of Copenhagen, Denmark. Spring 2007.

4. “Statistics in medical research”. Compulsory research course for physicians in specialty training (Obligatorisk Forskningstræningskursus Modul 2), Roskilde, Denmark. App. 3-4 annual courses from 2007 and onwards.

5. “The calcium homeostasis”. A-course on “Endocrinology” for physicians in training in Clinical Biochemistry, Vejle, Denmark. November 2009.

6. “Osteoporosis and calcium metabolic diseases”. A-course for endocrinologists in training (Dansul course), Hvidovre Hospital, Denmark. 2010.

7. ”The use of biochemical markers of bone turnover”. A-course for endocrinologist in training. Køge Hospital, Denmark. October 2013.

8. “How to write a scientific paper”, “Regulatory issues”, and “The Research Protocol”. Compulsory research course for physicians in specialty training (Obligatorisk Forskningstræningskursus Modul 1), University of Copenhagen, Denmark. March 2014.

9. “Calcium homeostasis” and “Bone turnover markers”. A-course in clinical biochemstry: “Endocrinology” for physicians in training in Clinical Biochemistry, Vejle, Denmark. October 2014.

OTHER POSTGRADUATE TEACHING 1. “Osteoporosis – prevention, diagnosis, and treatment”. Teaching of General Practitioners,

Maribo, Denmark. October 1996. 2. “Osteoporosis”. Teaching of health personnel, Kokkedal Health Center, Denmark. 1998. 3. “Hormone replacement therapy vs. selective estrogen modulators (SERMs)”. Course for

product specialists, Roche Pharmaceuticals, Hvidovre, Denmark. August 1998.


4. “Clinical trials and statistics”. Course for allied health personnel (nurses, physical therapists etc.) “Clinical decisions and research methodologies”. Danish Institute for Health and Nursing Research, Copenhagen and Sønderborg, Denmark. 2000, 2001, 2002.

5. “Gap junctions and ATP receptors – roles in the regulation of bone turnover”. Teaching of academics involved in research at the Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. March 2003.

6. “Future strategies in the bone cell lab”. Teaching of academics involved in research at the Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. April 2003.

7. “Biological fluids”. Course for technicians, Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. Spring 2004.

8. “Osteoporosis”. Course for technicians, Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. Spring 2004.

9. “Zink”. Course for technicians, Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. Spring 2004.

10. “Training of patients with osteoporosis”. Course for physical therapists on “Training of Elderly”, Bispebjerg Hospital, Denmark. February 2007.

11. “Osteoporosis – from basic science to clinical applications”. Teaching of physicians at Hvidovre Hospital, Denmark. Spring 2007.

12. “Calcium homeostasis”. Staff meeting at Dept. of Clinical Biochemistry, Hvidovre Hospital, Denmark. Fall 2007.

13. “Osteoporosis”. Staff meeting, Dept. of Clinical Biochemistry, Roskilde Hospital, Denmark. January 2008.

14. “Calcium signaling among bone cells”. Staff meeting, Dept. of Clinical Biochemistry, Roskilde Hospital, Denmark. February 2008.

15. “Analysis of monoclonal components in multiple myeloma”. Staff meeting, Dept. of Clinical Biochemistry, Roskilde Hospital, Denmark. June 2008.

16. “How to write a successful application and how to get the best possible start of the project.” Meeting on the Health Programme under the EU Framework Programme 7 arranged by the Danish Agency for Science, Technology and Innovation , Copenhagen, Denmark. August 2008.

17. “How to steer a Framework Programme 7 project – experiences from a coordinator”. Course on European FP7-projects arranged by Eurocenter, Copenhagen, Denmark. November 2009.

18. “How to steer a Framework Programme 7 project – experiences from a coordinator”. Course on European FP7-projects arranged by Eurocenter, Copenhagen, Denmark. May 2010.

19. “How to write a successful application and how to get the best possible start of the project.” Meeting on the Health Programme under the EU Framework Programme 7 arranged by the Danish Agency for Science, Technology and Innovation , Copenhagen, Denmark. August 2010.

20. “Bone biology”. Staff meeting at Division of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, Denmark. May 2012.

21. “How to steer a Framework Programme 7 project – experiences from a coordinator”. Course on European FP7-projects arranged by Eurocenter, Copenhagen, Denmark. June 2012.

22. “How to steer a Framework Programme 7 project – experiences from a coordinator”. Course on European FP7-projects arranged by Eurocenter, Copenhagen, Denmark. October 2012.

23. “The use of biochemical markers of bone turnover”. Teaching of physicians at Dept. of Endocrinology, Gentofte Hospital, Denmark. May 2014.

24. “Bone and bone turnover markers”. Teaching of technicians in Biolab, Division of Clinical Physiology and Nuclear Medicine, Glostrup Hospital, Denmark. May 2014.


5.4 PRE-GRADUATE TEACHING

1. Teaching of medical students, University of Copenhagen/Hvidovre Hospital 2003-2007 in

Clinical Biochemistry. Topics to include: Disorders of calcium homeostasis, Bone diseases, Hepatic and Biliary diseases, Renal diseases.

6. EVALUATION

6.1 MEMBERSHIP OF SCIENTIFIC EDITORIAL BOARD

1. Member of Editorial Board for Frontiers in Bone Endocrinology 2011-cont. 2. Lead Guest Editor for Journal of Osteoporosis 2011-2013

6.2 REVIEWING OF ARTICLES 1. American Journal of Physiology – Cell Physiology 2. Journal of Bone and Mineral Research 3. Bone 4. Calcified Tissue International 5. Purincergic Signalling 6. Frontiers in Bioscience 7. Frontiers in Endocrinology 8. Thorax 9. Hormone and Metabolic Research 10. Cell Biology International 11. Trends in Pharmaceutical Sciences 12. Cell and Tissue Research 13. Pharmacological Research 14. Sports Medicine 15. Acta Physiologica 16. Scandinavian Journal of Clinical and Laboratory Investigation (SJCLI) 17. WIRE’s Membrane Transport and Signaling 18. Yonsei Medicinal Journal 19. Journal of Innate Immunity

6.3 MEMBERSHIP OF EVALUATION COMMITTEES FOR ACADEMIC PERSONNEL 1. Member of the evaluation committee for the head of Dept. of Clinical Biochemistry,

Hvidovre Hospital, Denmark. 2004. 2. Chairman of the evaluation committee for senior consultant for Division of Clinical

Biochemistry, Glostrup Hospital, Denmark. 2011. 3. Chairman of the evaluation committee for chemist at the Division of Clinical Biochemistry,

Glostrup Hospital, Denmark. 2013. 4. Member of evaluation committee for employment of two PhD’s and one post doc at

Molecular Sleep Lab, Glostrup Hospital, Denmark. 2012.

6.4 MEMBERSHIP OF EVALUATION COMMITTEES FOR ACADEMIC DISSERTATIONS 1. Morten Karsdal (MSc) PhD thesis at SDU October 2004 2. Bodil-Cecilie Søndergaard (MD) PhD thesis at SDU September 2010 3. Sune Land Bloch (MD) PhD thesis at University of Copenhagen December 2010


4. Pia Rosgaard Jensen (MSc) PhD thesis at SDU 2012+2014 (revised) 5. Stinus Hansen (MD) PhD thesis at SDU January 2013 6. Olena Kucheryavenko (MSc) PhD thesis at SDU November 2013 Since 2007 (March) external examiner at Aarhus University in the Biological Sciences. Also served as external examiner at University of Copenhagen and at Roskilde University at several graduate exams.

6.5 MEMBERSHIP OF RESEARCH COUNCILS, SCIENTIFIC FUND COMMITTEES ETC. MEMBERSHIP OF RESEARCH COUNCILS

1. Member of the Research Council of The Copenhagen 2004-2006 Hospital Corporation (H:S Sundhedsvidenskabelige Forskningsråd) 2. Member of the Research Council at Glostrup Hospital 2014-cont. AD HOC EVALUATION OF GRANT APPLICATIONS

1. Research Grants Council Hong Kong 2004 2. North West Cancer Research Fund Scientific Committee 2006 3. Arthritis Research Campaign UK 2007 4. British Lung Foundation 2007 5. Arthritis Research UK Foundation 2011

7. RESEARCH COMMUNICATION

7.1 INVITED LECTURES AT CONFERENCES AND MEETINGS

INTERNATIONAL CONFERENCES AND MEETINGS 1. “ATP as extracellular messenger in intercellular calcium waves in osteoblastic cells”. Invited

lecture at mini-symposium on cell signaling, Washington University in St. Louis, MO; USA. April 1996.

2. “Osteoblast communication-a role for calcium waves”. Invited lecture at mini-symposium on cell signaling. Washington University, St. Louis, USA. July 1997.

3. “Osteoclast communication”. Invited lecture at Washington University, St. Louis, USA. August 1998.

4. “Status on calcium waves in human bone cells”. Invited lecture at Washington University, St. Louis, USA. September 1999.

5. “The role of gap junctional communication in bone diseases. Invited lecture at the First international meeting in consortium on the establishment of a Network of Excellence for the EU’s 6th FP. Paris September 2002

6. “The role of purinergic receptors in bone biology”. Invited lecture at seminar series on “Progress in Cell Biology and Cancer”. University of Navarra, Pamplona, Spain. April 2004.

7. “Calcium in the cross-talk between bone cells”. Invited lecture at the Congress on “Calcium in Health and Disease”. Rovaniemi, Finland. July 2004.

8. “The role of nucleotides and P2 receptors in intercellular calcium signaling in bone”. Invited lecture at the 8th International Symposium on Adenine and Adenosine Nucleotides, Ferrara, Italy. May 2006.

9. “Cellular signaling in bone – changes during aging and bone diseases”. Invited lecture at the IARU Workshop on “Ageing, longevity, and health”. Copenhagen, Denmark. October 2006.

10. “Purinergic signaling in the regulation of bone homeostasis”. Invited lecture at the 39th Sandbjerg Meeting on Membrane Transport, Sandbjerg, Denmark. May 2007.


11. “P2 receptor single nucleotide polymorphisms and bone metabolism”. Invited lecture at the Purines 2008 conference. Copenhagen, Denmark. July 2008.

12. “P2 receptor SNPs are associated with bone mass and bone strength after menopause”. Invited lecture at the ATPBone symposium, University of Liverpool, UK. November 2008.

13. “Intercellular calcium signaling and mechanotransduction in bone”. Invited lecture at seminar at University of Sheffield, UK. November 2008.

14. “P2X7 receptors and bone” Invited lecture at the European Calcified Tissue Society conference, Stockholm, Sweden. May 2012.

15. “P2X7 antagonists – a novel anabolic treatment for osteoporosis?”. Invited lecture at the Joint meeting of the German-Italian Purine Club, Rimini, Italy. September 2013

16. “The platelet-inhibitor clopidogrel increases risk of bone fractures in stroke patients”. Selected for oral presentation at the annual meeting in The American Society for Bone and Mineral Research, Baltimore, USA. October 2013.

17. “P2X and P2Y receptor polymorphisms and bone health and disease”. Invited lecture at the Purines 2014 conference, Bonn, Germany. July 2014.

NATIONAL CONFERENCES AND MEETINGS

1. “The use of video imaging for examination of bone cells. TNF-alfa as modulator of bone cell activity”. Invited lecture at scientific meeting at the Osteoporosis Research Center, Copenhagen Municipal Hospital, Copenhagen, Denmark. December 1994.

2. “Intercellular calcium waves”. Invited lecture at staff-meeting, RHIMA Center, Rigshospitalet, Copenhagen, Denmark. February 1997.

3. “Intercellular calcium waves in osteoblastic cells”. Invited lecture in meeting of The Danish Society for Molecular Gerontology, Aarhus, Denmark. March 1997.

4. “Calcium waves among bone cells”. Invited lecture in meeting of the Danish Bone and Tooth Society, Copenhagen, Denmark. March 1997.

5. “Intercellular calcium signals as communication among human bone cells”. Invited lecture in mini-symposium on calcium. Dept. of Nephrology, Rigshospitalet, Copenhagen, Denmark. September 1997.

6. “Bone cell biology – changes in osteoporosis”. Invited lecture at mini-symposium on osteoporosis, Copenhagen, Denmark. May 1999.

7. “The effect of gap junction openers on bone cells in vitro”. Invited lecture in meeting on gap junction openers arranged by Statens Serum Institute and Zealand Pharma A/S, Holte, Denmark. November 2001.

8. “Bone cells – past, now or never”. Invited lecture at symposium, Hvidovre Hospital, Hvidovre, Denmark. August 2002.

9. ”The P2X7 ko mouse and bone”. Invited presentation at meeting with GlaxoSmithKline, Harlow, UK. August 2002.

10. “The P2X7 ko mouse and bone”. Invited presentation at meeting with Rheoscience, Glostrup, Denmark. September 2002.

11. “Gap junctions and bone – status on research”. Invited presentation at Zealand Pharma A/S, Glostrup, Denmark. February 2003.

12. “Short-range intercellular calcium signaling in bone”. Invited lecture at meeting in Dept. of Endocrinology, Odense University Hospital, Odense, Denmark. June 2003.

13. “Osteoporosis – presentation of a specialty”. Invited presentation at meeting in the Laboratory Center, Hvidovre Hospital, Hvidovre, Denmark. August 2003.

14. “The effect of gap junction modifiers on bone in vitro and in vivo”. Invited presentation at meeting in Zealand Pharma A/S, Glostrup, Denmark. March 2004.

15. “Short-range intercellular calcium signaling in bone”. Presentation in relation to the defense of my doctoral thesis. University of Copenhagen, Denmark. October 2005.

16. “The P2X7 receptor and hip fractures”. Invited lecture in relation to project meeting at Kolding Hospital, Denmark. January 2006


17. “The P2X7 receptor and osteoporosis”. Invited lecture at meeting at Glostrup Hospital, Denmark. March 2006.

18. “The role of nucleotides and P2 receptors in intercellular calcium signaling in bone”. Invited lecture at seminar in Copenhagen Pharmaceutical University, Denmark. June 2006.

19. “PTH(1-34) but not alendronate increases bone quality in trabecular bone in a rat model of osteoporosis”. Glostrup Hospital, Denmark. September 2006.

20. “Calcium signaling in bone cells”. Invited lecture at meeting in Hvidovre Hospital, Denmark. November 2006.

21. “Short-range intercellular calcium signaling in bone”. Invited lecture at meeting in The Danish Bone Society, Aarhus University, Denmark. November 2006

22. “Short-range intercellular calcium signaling in bone”. Invited lecture at seminar at Aarhus University, Denmark. May 2007.

23. “Immobilization and osteoporosis – from laboratory to the clinic”. Invited presentation at staff-meeting, Roskilde Hospital, Denmark. Spring 2008.

24. “P2 receptors and bone”. Invited lecture at scientific meeting in Dept. of Clinical Biochemistry, Glostrup Hospital, Denmark. July 2008.

25. “How to write a good protocol for clinical trials”. Invited lecture at meeting on clinical trials in the Danish Pharmaceutical Society, University of Copenhagen, Denmark. Fall 2011.

26. “Training of osteoporosis patients”. Invited lecture at the annual Danish Congress of Sports Medicine, Kolding, Denmark. February 2013

27. “The use of biochemical bone markers”. Invited lecture at Eli Lilly Annual PTH Symposium, Copenhagen, Denmark. March 2013.

28. “The use of bone turnover markers in Denmark: A biochemical perspective”. Invited lecture at meeting in The Danish Bone Society, Odense, Denmark. May 2013.

29. “Adynamic bone disease – the view from the clinical biochemistry lab”. Invited lecture in Multidisciplinary Gentofte Symposium on adynamic bone disease, Gentofte Hospital, Denmark. November 2013.

30. “The platelet inhibitor clopidogrel increases risk of bone fractures”. Invited lecture at scientific meeting at Dept. of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark. March 2014.

7.2 CHAIRMAN AT INTERNATIONAL SCIENTIFIC CONFERENCES

1. Chairman at the European Calcified Tissue Society conference in the sessions “Cell-cell communication” and “Osteoclast biology”. Copenhagen, May 2007.

2. Chairman at the ATPBone minisymposium in relation to Purines 2008. Copenhagen June 2008.

3. Chairman at the Purines 2008 conference in the session “Purinergic signaling in bone and skeletal muscle”. Copenhagen. June 2008.

4. Chairman at the ATPBone symposium in Liverpool, UK. November 2008. 5. Chairman at the ATPBone symposium in Maastricht, Netherlands, May 2010. 6. Chairman at the ATPBone symposium in Brussels, Belgium, November 2010. 7. Chairman at the ATPBone symposium in Cardiff, UK. November 2011. 8. Chairman at the Purines 2014 conference in the session “Purinergic receptor polymorphisms

and their pathological implications”. Bonn, Germany. July 2014.

7.3 OTHER SCIENTIFIC PAPERS AND POSTERS

1. Sørensen OH, Kollerup G, Storm T, Thamsborg G, Jørgensen NR, Genant HK. Effect of long-term etidronate treatment on bone mass and spinal fracture rate. Osteoporosis International, Amsterdam, The Netherlands, May 18-23, 1996.


2. Short-term in vivo reliability of bone mass and soft tissue variables assessed by the Norland XR-26 scanner. Jørgensen NR, Jensen JEB, Madsen OR, Sørensen OH, Osteoporosis International, Amsterdam, The Netherlands, May 18-23, 1996.

3. Jørgensen NR, Geist S, Civitelli R, Steinberg TH. Intercellular calcium waves in osteoblastic cell lines occur by two different mechanisms. American Society for Bone and Mineral Research, Seattle, WA, September 1996.

4. Jørgensen NR, Geist S, Civitelli R, Steinberg TH. ATP-dependent and gap junction-dependent intercellular calcium signalins in osteoblastic cells. American Society of Cell Biology, San Francisco, CA, December 1996.

5. Brot C, Jørgensen NR, Hansen B, Sørensen OH. Reduced PTH levels among tobacco consuming perimenopausal women. European Calcified Tissue Society meeting, Vienna 1998.

6. Jørgensen NR, Henriksen Z, Eriksen EF, Sørensen OH, Civitelli R, Steinberg TH. Intercellular calcium signalling between human osteoblastic and osteoclastic cells. American Society for Bone and Mineral Research, San Francisco, CA, December 1998.

7. Teilmann SC, Jørgensen NR, Sørensen OH. Mechanisms of calcium signalling in osteoblast-like cells. IIIrd Baltic Bone Conference, Ronneby, Sweden, August 1999.

8. Rasmussen AM, Jørgensen NR, Hansen B, Sørensen HA, Sørensen OH. IIIrd Baltic Bone Conference, Ronneby, Sweden, August 1999.

9. Teilmann SC, Henriksen Z, Sørensen OH, Civitelli R, Steinberg TH, Jørgensen NR. Intercellular calcium signaling in the osteoblast-like cell line ROS 17/2.8 requires activation of voltage-gated calcium channels. American Society for Bone and Mineral Research, St. Louis, MO, September 1999.

10. Jørgensen NR, Henriksen Z, Sørensen OH, Civitelli R, Steinberg TH. In vitro differentiation of human osteoblast-like cells alters the predominant mechanism of intercellular calcium wave propagation. American Society for Bone and Mineral Research, St. Louis, MO, September 1999.

11. Jørgensen NR, Henriksen Z, Eriksen EF, Sørensen OH, Civitelli R, Steinberg TH. Co-cultures of human osteoblasts and osteoclasts can propagate intercellular calcium signals bidirectionally, and purinergic receptors seem to be involved in the signalling. Conference on nucleotides and purinergic receptors, Ferrara, Italy, September 2000.

12. Teilmann SC, Henriksen Z, Meier E, Petersen JS, Sørensen OH, Jørgensen NR. The gap junction opener ZS42-0123 enhances intercellular communication in osteoblastic cells. Gap junction meeting, Honolulu, HI, August 2001.

13. Jørgensen NR, Teilmann SC, Henriksen Z, Civitelli R, Sørensen OH. Steinberg TH. Mechanisms of calcium signaling in human bone marrow-derived stromal cells. American Society for Bone and Mineral Research, San Antonio, TX, September 2002.

14. Petersen JS, Kjølbye AL, Larsen BD, Harlow KW, Jepsen T, Meier E, Vinge MM, Nielsen MS, Holstein-Rathlou NH, Xing D, Martins JB, Teilmann SC, Sørensen OH, Jørgensen NR. Antiarrhythmic effects of the gap junction opener ZP123. Scandinavian Physiological Society Meeting, Århus, Denmark, 2002.

15. Ohlendorff S, Friberg-Hitz M, Tofteng CL, Jensen JEB, Jørgensen NR. A specific mutation in the P2X7 receptor DNA sequence may be responsible for impaired bone quality. European Calcified Tissue Society, Rome, Italy, May 2003.

16. Henriksen Z, Sørensen OH, Jørgensen NR. Dexamethasone and BMP-2 induce a more differentiated osteoblast phenotype in human bone marrow-derived stromal cells. European Calcified Tissue Society, Rome, Italy, May 2003.

17. Hansen SS, Henriksen Z, Petersen JS, Sørensen OH, Jørgensen NR. The AAP analogue ZP123 increases intercellular coupling in human osteoblasts in vitro. European Calcified Tissue Society, Rome, Italy, May 2003.

18. Jørgensen NR, Steinberg TH, Henriksen Z, Ohlendorff SD, Jensen JEB, Chessell IP, Sørensen OH. The purinergic P2X7 receptor is an inhibitor of bone resorption in mice. American Society for Bone and Mineral Research, Minneapolis, MN, September 2003.


19. Jørgensen NR. Calcium in the cross-talk between bone cells. The congress on “Calcium in Health and Disease”, Rovaniemi, Finland. July 5-7.

20. Ohlendorff SD, Jørgensen NR. The Glu496Ala polymorphism in the P2X7 receptor and bone loss. Meeting in the Danish Bone Research Society, Århus, Denmark, April 2004.

21. Petersen S, Henriksen Z, Ohlendorff SD, Jørgensen NR. Validation of a histomorphometric method to study bone formation and bone resorption in mice. European Calcified Tissue Society, Nice, France, June 2004.

22. Furlan F, Jørgensen NR, Rubinacci A, Heagen E, Villa I, Blasi F. Involvement of the urokinase receptor in bone homeostasis. American Society for Bone and Mineral Research, Seattle, WA, September 2004.

23. Solgaard M, Henriksen Z, Jørgensen NR. P2 receptors are involved in the regulation of proliferation of human osteoblastic cells. American Society for Bone and Mineral Research, Seattle, WA, September 2004.

24. Hansen SS, Ohlendorff SD, Henriksen Z, Teilmann J, Jørgensen NR. Variability in bone status among inbred strains of mice. American Society for Bone and Mineral Research, Seattle, WA, September 2004.

25. Henriksen Z, Thorklidsen C, Jensen JEB, Jørgensen NR. PTH increases bone mineral density and resistance to mechanical load in a rat model of osteoporosis. American Society for Bone and Mineral Research, Seattle, WA, September 2004.

26. Ohlendorff SD, Petersen S, Tofteng CL, Jørgensen NR. Effect of the P2X7 Glu396Ala polymorphism on osteoclast phenotype and survival. American Society for Bone and Mineral Research, Seattle, WA, September 2004.

27. Aaboe M, Bire K, Jørgensen NR, Terheyden H, Acil Y. Cultivation of minipig bone cells for bone tissue engineering: some pitfalls – some solutions. Meeting on jaw surgery, Amsterdam, June 2005.

28. Nielsen BR, Jørgensen NR, Schwarz P. Primary and secondary prophylaxis to the use of systemic glucocorticoid in primary health care. American Society for Bone and Mineral Research, Nashville, TN, September 2005.

29. Petersen S, Hansen SS, Jørgensen NR. Validation of histomorphometric indices in the vertebral spine of C57/BL mice. American Society for Bone and Mineral Research, Nashville, TN, September 2005.

30. Furlan F, Jørgensen NR, Jensen JEB, Rubinacci A, Mrak E, Marenzana M, Blasi F. Urokinase receptor is involved in bone remodelling by influencing osteoclast resorption. American Society for Bone and Mineral Research, Nashville, TN, September 2005.

31. Furlan F, Jørgensen NR, Jensen JEB, Mrak E, Rubinacci A, Verde P, Blasi F. Urokinase receptor is involved in bone remodelling by influencing osteoclast resorption. European Calcified Tissue Society, Prague, Czech Republic, May 2006.

32. Jørgensen NR. The role of P2 receptors and nucleotides in intercellular signalling in bone. 8th International Symposium on Adenine and Adenosine Nucleotides. Ferrara, Italy. May 2006.

33. Henriksen Z, Nissen N, Jørgensen NR. Functional P2X7 purinergic receptors are expressed in differentiated human osteoblasts. American Society for Bone and Mineral Research, Philadelphia, PA, September 2006.

34. Jørgensen NR, Thorkildsen C, Jensen JE, Petersen JS, Schwarz P. PTH increases bone mineral density and resistance to mechanical load in a rat model of osteoporosis. American Society for Bone and Mineral Research, Philadelphia, PA, September 2006.

35. Qvist A, Jørgensen NR, Schwarz P. Sequencing of the promoter region and exons 1a and 1b in the human calcium-sensing receptor gene. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

36. Henriksen Z, Nissen N, Schwarz P, Larsen TK, Jørgensen NR. P2X7 receptors are important in cell signalling and pore formation in mature primary human osteblasts. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.


37. Vestergaard P, Jørgensen NR, Mosekilde L, Schwarz P. Effects of strontium ranelate on bone mineral density and fracture risk – a meta-analysis. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

38. Nielsen BR, Jørgensen NR, Schwarz P. Primary and secondary prophylaxis to the use of inhaled glucocorticoid in primary health care. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

39. Syberg S, Petersen S, Jørgensen NR. Regional differences in P2X7 receptor regulation of bone metabolism in P2X7 knock-out mice. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

40. Ellegaard M, Stahlhut M, Petersen JS, Pedersen S, Jørgensen NR, Schwarz P. The effect of amylin(1-8) on bone in ovariectomized rats. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

41. Jensen JEB, Hitz M, Schwarz P, Jørgensen NR, Hyldstrup L. Biochemical markers of bone turnover; initial response to PTH(1-34) treatment and relation to changes in BMD and BMC. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

42. Vestergaard P, Jørgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk – a meta-analysis. European Calcified Tissue Society meeting, Copenhagen, Denmark, May 2007.

43. Petersen S, Syberg S, Henriksen Z, Schwarz P, Jensen JE, Sørensen OH, Jørgensen NR. The purinergic P2X7 receptor is responsible for ovariectomy-induced bone loss in mice. Prize poster at the research day, Copenhagen University Hospital Glostrup, Glostrup, Denmark. September 2007.

44. Henriksen Z, Nissen N, Schwarz P, Larsen TK, Jørgensen NR. P2X7 receptors are important in cell signalling and pore formation in mature primary human osteoblasts. Research day, Copenhagen University Hospital Glostrup, Glostrup, Denmark. September 2007.

45. Kringelbach TM, Bonewald L, Jørgensen NR. P2 receptor signalling in osteocyte networks. Research day, Copenhagen University Hospital Glostrup, Glostrup, Denmark. September 2007.

46. Syberg S, Petersen S, Teilmann J, Jensen JE, Schwarz P, Jørgensen NR. Ovariectomy-induced bone loss is reduced by the P2X7 agonist BzATP in mice. Research day, Copenhagen University Hospital Glostrup, Glostrup, Denmark. September 2007.

47. Johansen ZJ, Syberg S, Schwarz P, Jørgensen NR. The expression of in vitro markers in osteoblasts of different origin. Research day, Copenhagen University Hospital Glostrup, Glostrup, Denmark. September 2007.

48. Syberg S, Petersen S, Teilmann J, Jensen JE, Schwarz P, Jørgensen NR. Ovariectomy-induced bone loss is reduced by the P2X7 agonist BzATP in mice. American Society for Bone and Mineral Research, Honolulu, HI, September 2007.

49. Petersen S, Syberg S, Henriksen Z, Schwarz P, Jensen JE, Sørensen OH, Jørgensen NR. The purinergic P2X7 receptor is responsible for ovariectomy-induced bone loss in mice. Plenary poster at American Society for Bone and Mineral Research, Honolulu, HI, September 2007.

50. Bours MJL, van Helden S, Jørgensen NR, Dagnelie PC. Purinergic signaling in human osteoporosis: design of a cross-sectional genetic epidemiological study to detect disease-related aberrations in P2 receptor genes. Purines 2008. Copenhagen, June/July 2008.

51. Jørgensen NR, Ohlendorff SD, Aarup R, Petersen S, Schwarz P, Tofteng CL, Husted L, Langdahl BL, Wiley J. P2 receptor single nucleotide polymorphisms and bone metabolism. Purines 2008. Copenhagen, June/July 2008.

52. Kringelbach TM, Schwarz P, Novak I, Bonewald LF, Vang O, Jørgensen NR. P2 receptors are functionally expressed in MLO-Y4 osteocytes. Purines 2008. Copenhagen, June/July 2008.

53. Jørgensen NR, Husted LB, Schwarz P, Tofteng CL, Jensen JB, Nissen N, Eiken, Ødum L, Langdahl BL. Single Nucleotide Polymorphisms in the P2X7 Receptor Gene are associated with increased Postmenopausal Bone Loss and Fracture Incidence. American Society for Bone and Mineral Research, Montreal, Canada, September 2008.


54. Syberg S, Schwarz P, Jensen JEB, Jørgensen NR. The implications of P2X7 in bone metabolism in mice. The 7th Baltic Bone conference, Nyborg, Denmark, August 2009.

55. Kringelbach TM, Schwarz P, Novak I, Vang O, Bonewald LF, Jørgensen NR. The identification of P2 receptors in human osteocytes. The 7th Baltic Bone conference, Nyborg, Denmark, August 2009.

56. Petersen S, Syberg S, Schwarz P, Henriksen Z, Jørgensen NR. The Purinergic P2X7 Receptor might be involved in the Regulation of Fat Metabolism. American Society for Bone and Mineral Research, Denver, CO, USA, September 2009.

57. Henriksen Z, Brixen K, Eiken P, Jensen JEB, Langdahl BL, Schwarz P, Tofteng CL, Jørgensen NR. The Arg312Ser Single Nucleotide Polymorphism in the P2Y2 Receptor Gene is associated with Postmenopausal Rate of Bone Loss.American Society for Bone and Mineral Research, Denver, CO, USA, September 2009.

58. Bours MJL, Jørgensen NR, van Helden S, van Rhijn L, Geusens P, Wesselius A, Dagnelie PC. Design of a study on associations between P2 receptor polymorphisms and osteoporosis risk. EULAR, Copenhagen, Denmark, June 2009.

59. Hansen RR, Syberg S, Jørgensen NR, Ding M, Nasser A, Heegaard AM. Investigating the role of the purinergic P2X7 receptor in bone cancer pain. European Calcified Tissue Society meeting, Glasgow, Scotland, May 2010.

60. Syber S, Schwarz P, Petersen S, Jensen JEB, Steinberg TH, Gartland A, Teilmann J, Chessell I, Jørgensen NR. Bone status of P2X7 knockout mice in two different strains. Purines 2010 Conference, Tarragona, Spain, May/June 2010.

61. Schwarz P, Jørgensen NR, Jensen LT, Vestergaard P. Bone mineral density difference between right and left hip. International Osteoporosis Foundation, Rome, April 2010.

62. Dahl M, Jørgensen NR, Pinholt EM. Titanium granule carriers in adipose mesenchymal stem cell osteoblast in vitro mineralization. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

63. Syberg S, Petersen S, Orriss I, Schwarz P, Jørgensen NR. ATP treatment potentiates the positive effect of PTH on ovariectomy-induced bone loss in mice. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

64. Petersen S, Syberg S, Riis M, Schwarz P, Jørgensen NR. Differences in fat and bone metabolism between genders are partially mediated by the P2X7 receptor. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

65. Kvist TM, Aarup RR, Henriksen Z, Brixen K, Eiken P, Jensen JEB, Langdal BL, Tofteng CL, Schwarz P, Jørgensen NR. Association between SNPs in P2Y2 purinergic receptors in postmenopausal women and bone status in vivo. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

66. Schwarz P, Jørgensen NR, Mosekilde L, Vestergaard P. The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

67. Rasmussen AQ, Jørgensen NR, Schwarz P. Clinical and biochemical beneficial effect in four cases of familial hypocalciuric hypercalcemia treated with cinacalcet for up to three years. European Calcified Tissue Society meeting, Athens, Greece, May 2011.

68. Orriss IR, Syberg S, Brandao-Burch A, Hajjawi M, Arnett TR, Jorgensen NR. Clopidogrel

(Plavix), a P2Y12 receptor antagonist, inhibits osteoblast function in vitro and decreases trabecular bone in vivo. American Society for Bone and Mineral Research, San Diego, CA, USA, September 2011.

69. Jørgensen NR, Agca C, Syberg S, Wang N, Petersen S, Gartland A, Schwarz P, Agca Y. Increased expression of the purinergic P2Y2 receptor results in increased resorption and decreased bone in vivo. American Society for Bone and Mineral Research, San Diego, CA, USA, September 2011.

70. Petersen S, Syberg S, Schwarz P, Jørgensen NR. Effects of adenosine triphosphate (ATP) on bone and fat metabolism. American Society for Bone and Mineral Research, San Diego, CA, USA, September 2011.


71. Durup D, Plovst JR, Jensen LT, Frandsen E, Jørgensen NR, Petersen S, Heegaard AM. Assessement of Bone Associated Pain in the Aged Osteomalacic Rat. American Society for Bone and Mineral Research, San Diego, CA, USA, September 2011.

72. Vangsted A, Klausen T, Gang AO, Gimsing P, Abildgaard N, Andersen NF, GregersenH, Nexø BA, Vogel U, Schwarz P, Jørgensen NR. Genetic variation in the P2X7 receptor and the association to risk of disease, effect of high-dose treatment and bone disease in multiple myeloma. International Myeloma Workshop, Paris, May 2011.

73. Grove EJ, Wurtz M, Schwarz P, Jørgensen NR, Vestergaard P. Clopidogrel and risk of GI events. European Society of Cardiology, Munich, Germany, August 2012.

74. Xu J, Hansen SS, Jørgensen NR, Saurabh G. Role of P2Y2 receptors in neuropathic pain and sex difference. 22nd Neuropharmacology Conference, New Orleans, USA, October 2012.

75. Kvist TM, Petersen S, Frederiksen A, Syberg S, Jørgensen NR, Schwarz P. Inflammatorisk knogletab i en dyremodel - er P2X7 receptoren involveret? Danish Endocrine Society, Aalborg, Denmark, January 2013.

76. Jørgensen NR, Vestergaard P, Schwarz P, Iversen HK. The platelet-inhibitor Clopidogrel increases risk of bone fractures in stroke patients. American Society for Bone and Mineral Research, Baltimore, MD, USA, October 2013.

77. Petersen S, Syberg S, Schwarz P, Jørgensen NR. P2X7 receptors – do they have a role in commitment of mesenchymal stem cells? American Society for Bone and Mineral Research, Baltimore, MD, USA, October 2013.

78. Shanbhogue V, Hansen S, Jørgensen NR, Brixen K, Gravholt C. Bone geometry, volumetric density, microarchitecture and estimated bone strength in Klinefelter syndrome. Controversies in bone muscle and joint diseases, Brussels, Belgium, November 2013.

79. Rasmussen AQ, Jørgensen NR, Tfelt-Hansen J, Bevilacqua M, Schwarz P. A986S or the R990G polymorphism in CASR does not explain hypercalciuria and low normal serum calcium. European Congress of Endocrinology, Copenhagen, Denmark, April 2013.

80. Kvist, Petersen S, Frederiksen AG, Syberg S, Jørgensen NR, Schwarz P. Bone loss in inflammation-mediated osteoporosis – a role for the p2x7 receptor? European Congress of Endocrinology, Copenhagen, Denmark, April 2013.

81. Frederiksen AG, Lysgaard AL, Iversen E, Jørgensen NR, Schwarz P. BMI might be overestimated in elderly and old osteoporosis patients suffering vertebral fracture(s). European Union Geriatric Medicine Society meeting, Venice, Italy, October 2013.

82. Lysgaard AL, Frederiksen AG, Iversen E, Jørgensen NR, Schwarz P. Zoledronic acid does not improve BMD in elderly and old women after 24 months of treatment in an out-patient clinic. European Union Geriatric Medicine Society meeting, Venice, Italy, October 2013.

83. Knudsen A, Jørgensen NR, Katzenstein TL, Kronborg G, Obel N, Benfield T, Gerstoft J, Kjær A, Lebech A-M. Plasma plasminogen activator inhibitor-1 predicts first-time myocardial infarction in human immunodeficiency infected individuals. European AIDS Clinical Society, Brussels, Belgium, October 2013.

84. Syberg S, Agrawal A, Petersen S, Jensen JEB, Schwarz P, Gartland A, Bös M, Jørgensen NR. The P2X7 antagonist AFC-5261 rescues ovariectomy-induced bone loss in mice. American Society for Bone and Mineral Research, Houston, TX, USA, September 2014.

85. Dahl M, Syberg S, Jørgensen NR, Pinholt EM. 3D Scaffolding with Adipose Derived Mesenchymal Stem Cells – Their Osteogenicity and Osteoblast Mineralization. American Society for Bone and Mineral Research, Houston, TX, USA, September 2014.

86. Ellegaard M, Karlsson M, Lorentzon M, Ohlsson C, Mellström D, Ljunggren Ö, Schwarz P, Jørgensen NR. Association of P2Y2 Receptor Single-Nucleotide Polymorphism with Bone Mineral Density in Elderly Men. American Society for Bone and Mineral Research, Houston, TX, USA, September 2014.

87. Neldam CA, Jørgensen NR, Pinholt EM. Synchrotron µCT evaluation of peri-implant hard tissues. American Society for Bone and Mineral Research, Houston, TX, USA, September 2014.


88. Rasmussen AQ, Jørgensen NR, Schwarz P. Identification and functional characterization of a novel activating mutation in the human calcium-sensing receptor gene, responsible for autosomal dominant hypocalcemia. American Society for Bone and Mineral Research, Houston, TX, USA, September 2014.

89. Madsbad S, Jørgensen NR, Rabøl R, Chu PL, Stender-Petersen K, Jennum P. The impact of nocturnal hypoglycaemia on sleep in subjects with type 2 diabetes. European Association for the Study of Diabetes Meeting, Vienna, Austria, September 2014.

90. Gurzawska K, Svava R, Yihua Y, Haugshøj K, Dirscher K, Nielsen MW, Jørgensen B, Ulvskov P, Berglundh T, Jørgensen NR, Gotfredsen K. Surface nanocoating with pectins of titanium implants in rabbit model. International Association for Dental Research, 2014.

91. Madsbad S, Jørgensen NR, Rabøl R, Chu PL, Stender-Petersen K, Jennum P. The impact of nocturnal hypoglycaemia on sleep in subjects with type 2 diabetes. 10th International Diabetes Federation-Western Pacific Region Congress, Singapore, November 2014.

92. Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, Andersen UB, Rostrup E, Glenthøj BY, Ebdrup BH. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention trial - the TAO study.

In addition, my group has presented several posters at the scientific meetings at Hvidovre Hospital and Glostrup Hospital every year (“Forskningens Dag”).

7.4 PUBLICATIONS AND PRESENTATIONS IN POPULAR SCIENTIFIC CONNECTION

PAPERS IN POPULAR SCIENTIFIC CONNECTION 1. Jørgensen NR, Vadstrup S. Instruction for patients in treatment with Didronate. PraxInfo

1995. 2. Jensen JEB, Jørgensen NR. Knoglescanning ved osteoporose, hvor skal man måle og hvilken

metode skal anvendes? (Bone scan in osteoporosis – where to measure and which method to use”. InfoMed 2001;12:1-4.

3. Jørgensen NR. Når knoglerne snakker (When bones talk). Apropos 2003. 4. Schwarz P, Jørgensen NR. Ung og med øget risiko for knogleskørhed (Young and with

increased risk of osteoporosis). Apropos 2004;4:24-25. 5. Jørgensen NR. Risk factors for osteoporosis. Best Practice 2008. 6. Jørgensen NR, Schwarz P. Et dansk ledet europæisk samarbejde om osteporoseforskning.

Apropos 2011.

PRESENTATIONS IN POPULAR SCIENTIFIC CONNECTION

1. “Bone biology and osteoporosis”. Invited lecture. Open University (Folkeuniversitetet) series on “Osteoporosis”, University of Copenhagen, Denmark. November 1998.


3. “Bone biology and osteoporosis”. Invited lecture. Open University (Folkeuniversitetet) series on “Osteoporosis”, Roskilde University, Denmark. November 1999.


5. ”Bone biology”. Invited lecture. Open University (Folkeuniversitetet) series on “Osteoporosis”, University of Copenhagen, Denmark. Fall 2005.

6. ”Bone biology”. Invited lecture. Open University (Folkeuniversitetet) series on “Osteoporosis”, University of Copenhagen, Denmark. Spring 2009.

7. TV interview on new developments in osteoporosis research. TV2 News (6 minutes direct interview). August 2011.

8. Radio interview on new developments in osteoporosis research. Radioavisen. August 2011.


9. “Osteoporosis at the cellular level – how does the treatment work?” Invited lecture. Open University (Folkeuniversitetet) series on “Osteoporosis”, University of Copenhagen, Denmark. February 2012.

10. “ATPBone – a European research collaboration on osteoporosis”. Invited lecture. The Danish Osteoporosis Patient Organization (Osteoporoseforeningen), Slagelse, Denmark. Spring 2012.

11. “ATPBone – a European research collaboration on osteoporosis”. Invited lecture. The Danish Osteoporosis Patient Organization (Osteoporoseforeningen), Holbæk, Denmark. Spring 2012.

12. Radio interview on the risk of fractures when taking clopidogrel. Radio 24/7 direct interview. Spring 2013.

13. “New knowledge about osteoporosis – the results of a joint European project”. Invited lecture. The Danish Osteoporosis Patient Organization (Osteoporoseforeningen), Næstved, Denmark. October 2014.

8. RESEARCH FUNDING

8.1 FUNDING AWARDS HELD DURING THE LAST FIVE YEARS

AS MAIN APPLICANT 1. European Commission’s 7th Framework Programme. 2008-2010 Kr. 22.500.000,-

I was coordinator. Project on the role of P2 receptors in bone metabolism 2. Toyota Fonden. For purchase of equipment (NovoStar) 2010 Kr. 150.000,- 3. The Danish Research Council. From 2013-2016 Kr. 1.800.000,-

Project on mechanotransduction in bone and the role of P2 receptors 4. Novo Nordisk Foundation. 2013. For purchase of loading equipment Kr. 700.000,-

AS CO-APPLICANT 5. Copenhagen County Hospital Corporation. 2006-2009 Kr. 3.000.000,-

Main applicant: Peter Schwarz 6. The Danish Research Council. 2009-2012 Kr. 1.082.550,-

Main applicant: Peter Schwarz 7. University of Copenhagen. PhD stipend. 2009-2012 Kr. 525.000,-

Main applicant: Tina Marie Kringelbach 8. The Danish Research Council (Det Strategiske Forskningsråd). 2008-2012 Kr. 9.000.000,-

Main applicant: Iben Damager 9. University of Copenhagen (Puljen for interdiscipl. forskning). 2013-2016 Kr. 27.892.000,-

Main applicant: Sine Larsen

8.2 PARTICIPATION IN INTERNATIONAL RESEARCH PROGRAMMES

1. Coordinator of the ATPBone consortium which was funded by the European Commission’s 7th Framework Programme. 2008-2010

2. Participant in EU COST action aiming at establishing a pan-European Network in Inflammation. Application is submitted to the EU. 2014.

3. Co-founder and member of steering committee of consortium to apply for EU funding through the Horizon2020 program with the topic of “The role of purinergic signaling in complications to type 2 diabetes”. 2014.

8.3 EXISTING COMMERCIAL COLLABORATIONS


1. Novo Nordisk: “A trial to investigate the impact of nocturnal hypoglycaemia on sleep in subjects with type 2 diabetes”. Scientific joint project in which I serve as the laboratory coordinator. Funding from the project covers the cost of blood sampling, analysis and coordination. Budget for laboratory part kr. 2.850.000,-. 2012-2014

2. Lundbeck Pharma A/S: Collaborative project on the effects of P2X7 receptor compounds on bone biology. Does not involve direct financial remuneration, but instead access to compounds, technology and knowhow. CONFIDENTIAL INFORMATION

3. Lundbeck Pharma A/S. Collaborative project on a characterization of a newly discovered mutation leading to a severe syndrome involving a bone phenotype of low bone mass. CONFIDENTIAL INFORMATION

4. Lundbeck Pharma A/S: Negotiations on a project addressing the effects of P2X7 compounds on P2X7 receptors with different genetic mutations. Possible involvement in a larger grans application on the subject. CONFIDENTIAL INFORMATION

9. RESEARCH COLLABORATIONS

INTERNATIONAL COLLABORATIONS

1. Professor Francesco Di Virgilio, University of Ferrara, Italy on projects investigating the role of the P2X7 receptor in cancer.

2. Professor James Wiley, University of Melbourne, Australia on projects determining the role of P2 receptor polymorphisms in bone health and disease

3. Dr. Alison Gartland, University of Sheffield, UK, on projects relating to P2X7 and P2Y2 knockout mouse models. Also on in vivo studies of different P2 receptor active compounds.

4. Dr. Isabel Orriss, Royal Veterinary College, London, UK on the side effects of platelet inhibitors on bone

5. Professor Yuksel Agca, University of Missouri in Columbia, USA. Projects on P2Y2 overexpressing rats and bone and on studies on the effects of ovary transplant on bone mass and quality.

NATIONAL COLLABORATIONS

1. Research Center for Ageing and Osteoporosis (FAO). Close collaboration with Professor Peter Schwarz (University of Copenhagen) and Professor Bo Abrahamsen (OPEN, University of Southern Denmark). My research group is part of the research center, so we have several joint projects on bone/osteporosis.

2. ATPSignal: Resarch network with Professor Ivana Novak, Assoc. Professor Anne-Marie Heegaard and Assoc. Professor Stephan Pless (all University of Copenhagen). Joint projects on P2X7 receptor biology, and with regular scientific meetings with participation of members from all four groups.

3. CoNeXT: Interdisciplinary research group with Professor Sine Larsen as the principal investigator. The collaboration focuses on “Fertilizing the ground and harvesting the full potential of the new neutron and X-ray research infrastructures close to Copenhagen University”.

4. Assoc. Professor Helle Iversen, Dept. of Neurology, Glostrup Hospital. Collaboration on projects relating to bone health in stroke patients including the clinical effects of clopidogrel on bone in stroke patients.

5. Assoc. Professor Annette Vangsted on projects on the role of the P2X7 receptor in multiple myeloma and in myeloma bone disease.

6. Professor Poul Jennum, Dept. of Neurophysiology, Glostrup Hospital, Professor Sten Madsbad, Dept. of Endocrinology, Hvidovre Hospital, and Novo Nordisk on the impact of nocturnal hypoglycaemia on sleep and hormones in type 2 diabetes patients.


7. Assoc. Professor Eva Wulff Helge, University of Copenhagen on several projects addressing physical exercise and bone turnover markers.

8. Assoc. Professor Henrik Vestergaard, University of Copenhagen on a project on changes in bone turnover after bariatric surgery.

9. Assoc. Professor Pia Eiken, Hillerød Hospital, on project on bone metabolism in patients with type 2 diabetes.

10. Professor Ming Ding, SDU, on several projects addressing the role of P2 receptor signaling and bone structure in vivo.

11. Dr. Stinus Hansen, Esbjerg Hospital, on a project examining the effect of gastric bypass on bone structure (HR-pQCT) and bone turnover markers.

12. Professor Peter Vestergaard, Aalborg University, on project addressing the role of clopidogrel and other platelet inhibitors in fracture risk (epidemiological studies).

13. Assoc. Professor Ole Rintek Madsen, Gentofte Hospital on project on bone turnover markers in rheumatological patients treated with biological anti-rheumatic agents.

14. Dr. Trine Jensen David, Hvidovre Hospital and Professor Mikkel Østergaard, VRR, Glostrup Hospital on a project on bone metabolism in rheumatoid arthritis patients in DMARD therapy.

15. Professor Allan Linneberg, Glostrup Hospital on project on reference ranges of bone turnover markers in healthy individuals as well as other studies in the Glostrup cohorts.

16. Professor Merete Hetland on the Danish Rheuma Biobank. 17. Lundbeck Pharma A/S: Collaborative project on the effects of P2X7 receptor compounds on

bone biology. 18. Lundbeck Pharma A/S. Collaborative project on a characterization of a newly discovered

mutation leading to a severe syndrome involving a bone phenotype of low bone mass.

Documents

NIKLAS RYE JØRGENSEN, JULY 2014 - Rigshospitalet · Niklas Rye Jørgensen • 61670065• [email protected] Page 7 1. Jørgensen NR, Syberg S, Ellegaard M. P2X receptor roles in